PhoreMost Ltd Revenue and Competitors

PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted' therapies more efficiently to market and pass these cost savings onto patients. PhoreMost is aiming to remove barriers to new drug development with its novel SITESEEKER technology, a live-cell phenotypic assay system that can rapidly identify unexpected, or “cryptic” druggable sites in specific disease driving targets and pathways that can't be readily seen using conventional non-cell based analytical methods. SITESEEKER employs diverse (billions of elements) biological screening libraries of small 3-dimensional protein-folds, which when delivered into cell-based phenotypic assays interact on a genome-wide scale with host-cell proteins to describe new druggable space that is intimately linked to disease causation. This process, called Protein Interference, lies at the heart of the SITESEEKER platform and differs fundamentally from other genome-based target screening technologies, such as RNAi and CRISPR, in operating directly at the protein level, so that new druggable space can be defined as an inherent part of the target-function screening process.